A Phase 3 interventional study of Murepavadin and Two anti-pseudomonal antibiotics in Pneumonia, sponsored by Polyphor Ltd.. Terminated at 61 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-28.
Sponsored by Polyphor Ltd. · Phase 3, Interventional, and Treatment
This is a phase 3, multicenter, open-label, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability, and pharmacokinetics of intravenous murepavadin combined with of one anti-pseudononas antibiotic with that of two anti-pseudomonas antibiotics in the treatment of ventilator-associated bacterial pneumonia (VABP) in adult subjects.
Key Inclusion Criteria:
Key Exclusion Criteria:
Murepavadin IV + one anti-pseudomonal antibiotic
Drug: Murepavadin
Association of 2 anti-pseudomonal antibiotics
Drug: Two anti-pseudomonal antibiotics
Murepavadin IV every 8 hours + 1 anti-pseudomonal antibiotic (Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin)
Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin
Clinical cure rate
Time frame: 21-24 days after start of study treatment
This study is terminated, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Polyphor Ltd.